MindMaze Therapeutics Holding SA

MindMaze Therapeutics Holding SA's next confirmed earnings release is scheduled for April 15, 2027.

As of December 31, 2025, MindMaze Therapeutics Holding SA has 152.60M shares outstanding.

As of December 31, 2025, MindMaze Therapeutics Holding SA maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.71, indicating elevated leverage, while an interest coverage ratio of -33.37 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, MindMaze Therapeutics Holding SA posted a negative return on equity (ROE) of -51.56, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -38.38, reflecting losses generated across the asset base. Inventory turnover of 0.09 indicates how many times MindMaze Therapeutics Holding SA sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, MindMaze Therapeutics Holding SA generated 642,000.00 in revenue and converted that into -9.91M in net income, yielding earnings per share of -0.48. EBITDA reached -8.88M, while operating income came in at -10.51M.

As of December 31, 2025, MindMaze Therapeutics Holding SA holds 9.47M in cash and equivalents against 1.81M in total debt, resulting in a net debt position of -9.47M. Total book value stands at 38.34M, with working capital of 2.22M providing operational flexibility.

MindMaze Therapeutics Holding SA produced -7.21M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -22,000.00 in capital expenditures, free cash flow totaled -7.23M - equivalent to -0.35 per share.

Over the twelve months ended December 31, 2025, MindMaze Therapeutics Holding SA posted a gross margin of 92.06, reflecting its pricing power and cost economics. The operating margin of -1,637.85 and net profit margin of -1,542.99 provide insight into operational efficiency.

MindMaze Therapeutics Holding SA's most recent stock split took place on May 5, 2023 with a 400:1 split ratio.